Close

Ariad (ARIA) Shares Plunge 10+% as Results of Phase 2 Study of Ponatinib Show Serious Side Effects

November 7, 2011 11:20 AM EST
Shares of Ariad Pharma (Nasdaq: ARIA) are crumbling in early-morning trade Monday. After opening about flat, the stock is now down 10 percent for the session. Downside intensified sharply just after 10:30am ET.

An abstract from the American Society of Hematology was released earlier demonstrating serious side effects in 17 percent of chronic myeloid leukemia patients using the experimental ponatinib. About 15 percent of patients stopped therapy with the drug.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

FDA, Momentum Movers